FDA Rejects Capricor's Duchenne Therapy a Second Time, Citing Lack of Efficacy
The FDA has rejected Capricor's cell therapy for Duchenne muscular dystrophy a second time, citing serious flaws in its clinical trial.
For the second time, the FDA has rejected deramiocel, Capricor Therapeutics' experimental cell therapy for Duchenne muscular dystrophy — a devastating and progressive muscle-wasting disease that primarily affects young boys. The decision marks a significant setback for patients, families, and investors, with Capricor's shares sinking following the announcement. While the agency previously flagged serious problems with HOPE-3, the supporting clinical trial — including unblinding and protocol violations — new reporting from STAT News underscores that the more fundamental issue was efficacy: the drug simply didn't work. A public pressure campaign by patient advocates was unable to change that underlying reality. This second complete response letter compounds earlier regulatory setbacks for Capricor. Duchenne muscular dystrophy has very few approved treatments, and patients typically face severe, progressive muscle deterioration. The rejection leaves a significant gap that deramiocel had been positioned to fill, and the path forward for the program, if any exists, remains unclear.
Why it matters
Duchenne muscular dystrophy is a rare, life-shortening disease with limited treatment options, making every regulatory rejection a direct blow to a small and vulnerable patient population. The repeated failure of deramiocel's application also raises broader questions about the evidentiary standards for rare-disease cell therapies.
What's next
It is not yet clear whether Capricor plans to conduct a new trial or pursue another regulatory pathway to seek approval for deramiocel.
Key facts
- The FDA issued a second rejection of Capricor Therapeutics' cell therapy deramiocel for Duchenne muscular dystrophy
- The FDA cited unblinding and protocol violations in the HOPE-3 clinical trial as significant issues
- Unblinding in a clinical trial means participants or investigators may have learned who received treatment versus placebo, compromising results
- This is at least the second complete response letter Capricor has received from the FDA for this therapy
- Duchenne muscular dystrophy is a progressive, fatal muscle-wasting disease primarily affecting boys with very few approved treatments
Bias & framing notes
Both sources confirm the rejection and the HOPE-3 trial issues, but Endpoints News provided more specific detail about the nature of the violations (unblinding, protocol violations), while STAT News leaned into the narrative that the rejection was foreseeable. Neither source included a substantive response from Capricor Therapeutics, leaving the company's perspective absent from the reporting.
NewsClear — neutral news & congressional tracking · Bill of the Week